Langdon L. Miller

Internal Medicine
3057 Perkins Ln W
Seattle, WA 98199

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.

Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.

Journal: NEJM evidence
Published: January 01, 2022

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.

Journal: Blood
Published: July 27, 2020

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.

Journal: Blood
Published: March 02, 2015

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

Journal: Blood
Published: March 12, 2014

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

Journal: Blood
Published: March 12, 2014

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Journal: The New England journal of medicine
Published: January 24, 2014

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

Journal: The New England journal of medicine
Published: January 24, 2014

PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.

PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.

Journal: Blood
Published: January 03, 2012
Showing 1-8 of 8

Last Updated: 09/26/2026